CD34 and autoimmune thrombocytopenic purpura: Furthermore, a comparative analysis of pre-treatment laboratory indicators revealed that ITGV-BMFs patients exhibited lower CD34% in bone marrow, higher MCV, MCH, and RET than those with classic ITP (p < 0.001) (Table 1; Figure 2).